Omnicell, Inc.

DB:OC9 Stock Report

Market Cap: €1.9b

Omnicell Valuation

Is OC9 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of OC9 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: OC9 (€42.6) is trading below our estimate of fair value (€57.19)

Significantly Below Fair Value: OC9 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for OC9?

Key metric: As OC9 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for OC9. This is calculated by dividing OC9's market cap by their current revenue.
What is OC9's PS Ratio?
PS Ratio1.9x
SalesUS$1.06b
Market CapUS$2.00b

Price to Sales Ratio vs Peers

How does OC9's PS Ratio compare to its peers?

The above table shows the PS ratio for OC9 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.8x
AFX Carl Zeiss Meditec
2x6.4%€4.1b
DRW3 Drägerwerk KGaA
0.3x4.2%€805.2m
EUZ Eckert & Ziegler
3.3x5.4%€928.9m
SBS Stratec
1.4x7.7%€361.6m
OC9 Omnicell
1.9x5.9%€2.0b

Price-To-Sales vs Peers: OC9 is expensive based on its Price-To-Sales Ratio (1.9x) compared to the peer average (1.8x).

Price to Sales Ratio vs Industry

How does OC9's PS Ratio compare vs other companies in the DE Medical Equipment Industry?

4 CompaniesPrice / SalesEstimated GrowthMarket Cap
DRW3 Drägerwerk KGaA
0.3x4.2%US$838.10m
PHH2 Paul Hartmann
0.3xn/aUS$824.35m
U4W0 Quotient
0.07xn/aUS$2.78m
MF6 MagForce
0.3xn/aUS$404.27k
No more companies available in this PS range
OC9 1.9xIndustry Avg. 3.4xNo. of Companies4PS01.63.24.86.48+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: OC9 is good value based on its Price-To-Sales Ratio (1.9x) compared to the European Medical Equipment industry average (3.4x).

Price to Sales Ratio vs Fair Ratio

What is OC9's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

OC9 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.9x
Fair PS Ratio1.3x

Price-To-Sales vs Fair Ratio: OC9 is expensive based on its Price-To-Sales Ratio (1.9x) compared to the estimated Fair Price-To-Sales Ratio (1.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst OC9 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€42.60
€53.90
+26.5%
14.4%€65.74€41.92n/a7
Dec ’25€43.80
€53.19
+21.4%
14.7%€65.21€41.58n/a7
Nov ’25€44.40
€52.20
+17.6%
17.4%€63.67€34.14n/a7
Oct ’25€38.60
€38.80
+0.5%
20.8%€54.50€26.81n/a7
Sep ’25€40.00
€38.80
-3.0%
20.8%€54.50€26.81n/a7
Aug ’25€26.80
€32.96
+23.0%
21.2%€41.70€24.09n/a7
Jul ’25€25.20
€30.79
+22.2%
19.0%€37.16€24.15n/a7
Jun ’25€30.00
€30.79
+2.6%
19.0%€37.16€24.15n/a7
May ’25€25.20
€30.40
+20.6%
19.0%€36.54€23.75n/a7
Apr ’25€26.80
€30.40
+13.4%
19.0%€36.54€23.75n/a7
Mar ’25€24.00
€31.12
+29.7%
18.0%€37.08€24.10n/a7
Feb ’25€29.60
€34.52
+16.6%
20.2%€46.12€25.82n/a7
Jan ’25€35.00
€36.68
+4.8%
22.5%€46.63€26.11n/a6
Dec ’24€30.60
€36.68
+19.9%
22.5%€46.63€26.11€43.806
Nov ’24€33.40
€58.53
+75.3%
17.7%€70.81€36.82€44.407
Oct ’24€42.20
€65.76
+55.8%
19.7%€83.27€36.90€38.608
Sep ’24€52.00
€64.48
+24.0%
13.4%€80.42€51.18€40.009
Aug ’24€56.00
€63.49
+13.4%
14.1%€79.07€50.32€26.809
Jul ’24€67.50
€64.45
-4.5%
11.8%€80.39€53.90€25.209
Jun ’24€67.50
€62.93
-6.8%
8.2%€69.08€54.34€30.009
May ’24€54.50
€60.49
+11.0%
8.9%€68.62€52.15€25.209
Apr ’24€53.50
€61.38
+14.7%
9.5%€70.34€53.46€26.809
Mar ’24€53.50
€61.38
+14.7%
9.5%€70.34€53.46€24.009
Feb ’24€51.50
€60.62
+17.7%
12.1%€69.02€49.70€29.608
Jan ’24€45.00
€61.88
+37.5%
13.3%€70.20€50.54€35.009
Dec ’23€48.80
€72.87
+49.3%
37.7%€147.24€52.31€30.609

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 11:03
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Omnicell, Inc. is covered by 26 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
K. JuhngBB&T Capital Markets
William SutherlandBenchmark Company
Raymond MyersBenchmark Company